You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

Atazanavir - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Drug Prices for atazanavir

See drug prices for atazanavir

Generic filers with tentative approvals for ATAZANAVIR

Applicant	Application No.	Strength	Dosage Form
Start Trial	Start Trial	300MG/100MG	TABLET; ORAL
Start Trial	Start Trial	200MG	CAPSULE; ORAL
Start Trial	Start Trial	150MG	CAPSULE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for atazanavir

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	091673-004	Apr 22, 2014	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Mylan	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	208177-001	Sep 24, 2018		DISCN	No	No	Start Trial	Start Trial				Start Trial
Bristol Myers Squibb	REYATAZ	atazanavir sulfate	CAPSULE;ORAL	021567-004	Oct 16, 2006	AB	RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Bristol-myers Squibb	EVOTAZ	atazanavir sulfate; cobicistat	TABLET;ORAL	206353-001	Jan 29, 2015		RX	Yes	Yes	Start Trial	Start Trial	Y	Y		Start Trial
Bristol Myers Squibb	REYATAZ	atazanavir sulfate	CAPSULE;ORAL	021567-003	Jun 20, 2003	AB	RX	Yes	No	Start Trial	Start Trial				Start Trial
Amneal	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	209717-002	Jun 1, 2020	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Amneal	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	209717-004	Jun 1, 2020	AB	RX	No	No	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow

Boehringer Ingelheim

Express Scripts

Harvard Business School

McKesson

Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.